FDA approves add-on drug for adults with rare form of blood vessel inflammation

FDA has approved Tavneos (avacopan) as an add-on treatment to standard therapy including glucocorticoids for adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Tavneos helps to reduce blood vessel inflammation and offers patients an additional t

Source: FDA Center for Drug Evaluation and Research - What's New - October 13, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news